SAN FRANCISCO, Oct. 4, 2017 — King & Spalding advised Apama Medical in its acquisition by Boston Scientific Corp. (NYSE: BSX) in a transaction consisting of $175 million in cash up front and a maximum of $125 in contingent payments over the period of 2018-2020, based on achievements of clinical and regulatory milestones.
Apama Medical, based in Campbell, Calif., is a privately held company that is developing the Apama Radiofrequency Balloon Catheter System for the treatment of atrial fibrillation, a common heart rhythm disorder estimated to affect more than 33 million people worldwide. Massachusetts-based Boston Scientific is a global developer, manufacturer and marketer of medical devices.
The King & Spalding team on this transaction was led by partner Geoff Leonard (San Francisco) and included senior associate Robert Benson (Atlanta) and associate Katy Alexander (San Francisco).
About King & Spalding
Celebrating more than 130 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 1,000 lawyers in 20 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality, and dedication to understanding the business and culture of its clients. More information is available at www.kslaw.com.